Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
Ryan Allway February 15th, 2023 Psychedelics, Top News The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s Cannamide™ and classical psychedelics Tel Aviv, Israel / Vancouver, Canada, Feb. 15, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND),... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )